Nevada’s Vetoed Insulin Cost Transparency Bill Returns, as California Advances Several Pricing Measures Post author:Sam Post published:June 5, 2017 Post category:Drug Industry Daily Lawmakers in Nevada and California continue to target drugmakers in health care proposals. Source: Drug Industry Daily You Might Also Like FDA Seeks to Speed Insulin Biosimilar Approvals with New Guidance November 25, 2019 Meeting Planner — Week of June 12, 2023 June 14, 2023 House Passes Bill to Cap Insulin Prices March 31, 2022